[BioS]AVL, 4-1BBxPD-L1 double antibody “Started US clinical trial”

[BioS]AVL, 4-1BBxPD-L1 double antibody “Started US clinical trial”

by

Dose-limiting toxicity, safety, tolerability, preliminary efficacy, etc. for 36 patients with advanced solid cancer in phase 1 clinical trials

The US clinical trial of’ABL503′, a dual antibody candidate, which is jointly developed by Chinese I-Mab Biopharma, as an anticancer drug, has begun. This is the first clinical trial of a biantibody to which AVL Bio’s 4-1BB immune anticancer drug platform has been applied.

ABL503 is a dual-antibody anticancer drug that simultaneously targets PD-L1 and 4-1BB. ABL503 is expected to be able to overcome the toxic side effects of existing 4-1BB monoclonal antibodies by acting specifically in the tumor microenvironment that overexpresses PD-L1.

AVL announced on the 5th that it had first administered ABL503 to patients at Next Oncology in Texas on the 1st (local time). This phase 1 clinical trial was designed to evaluate dose-limiting toxicity (DLT), safety, tolerability, and preliminary efficacy in 36 patients with advanced solid cancer (NCT04762641). Clinical trials are conducted at 6 clinical institutions including Next Oncology Cancer Center, Yale Medical Center, and UCLA Medical Center.

Anthony W. Tolcher, MD, Doctor of Medicine at Next Oncology said, “Up to now, 4-1BB-based candidates have encountered many challenges in the clinical process due to serious toxic side effects, but ABL503 is expected to overcome these problems sufficiently. “We hope that through careful research, we can contribute to the development of treatments that can improve the quality of life and increase the viability of cancer patients.”

Lee Sang-hoon, CEO of ABL Bio, said, “The clinical phase 1 study of ABL503 is proceeding smoothly as planned.” “Grabody of ABL Bio induces attacking cancer only in the tumor microenvironment to overcome the toxicity problem of the existing 4-1BB antibody. As the -T’ dual antibody platform is the first to be tested on clinical trials, we look forward to demonstrating the company’s technology in the field of immunotherapy through good results.”

On the other hand, ABL Bio has also received approval from the US FDA last month for the phase 1 clinical IND of the new target dual antibody immuno-anticancer drug ABL111 (Claudin18.2X4-1BB), and plans to register the first patient in June.

.Source